1,151
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP)

ORCID Icon, , , , , , ORCID Icon, , ORCID Icon & show all
Pages 453-459 | Received 19 Aug 2022, Accepted 01 Nov 2022, Published online: 11 Nov 2022

References

  • McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597–1604.
  • Kotilea K, Bontems P, Touati E. Epidemiology, diagnosis and risk factors of Helicobacter pylori infection. Adv Exp Med Biol. 2019;1149:17–33.
  • Mitchell HM. The epidemiology of Helicobacter pylori. Curr Top Microbiol Immunol. 1999;241:11–30.
  • Kinoshita H, Hayakawa Y, Koike K. Metaplasia in the Stomach-Precursor of gastric cancer? Int J Mol Sci. 2017;18(10):2063.
  • Schistosomes, liver flukes and Helicobacter pylori IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 june 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
  • de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e90.
  • Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer. Lancet. 2017;390(10110):2383–2396.
  • Nie S, Chen T, Yang X, et al. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014;27(7):645–653.
  • Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–831.
  • Chen CC, Liou JM, Lee YC, et al. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1–22.
  • Okushin K, Tsutsumi T, Ikeuchi K, et al. Helicobacter pylori infection and liver diseases: epidemiology and insights into pathogenesis. World J Gastroenterol. 2018;24(32):3617–3625.
  • Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10(1):10–27.
  • Kaewpitoon SJ, Loyd RA, Rujirakul R, et al. Helicobacter species are possible risk factors of cholangiocarcinoma. Asian Pac J Cancer Prev. 2016;17(1):37–44.
  • Liu IL, Tsai CH, Hsu CH, et al. Helicobacter pylori infection and the risk of colorectal cancer: a nationwide population-based cohort study. QJM. 2019;112(10):787–792.
  • Malfertheiner P, Megraud F, O'Morain CA, European Helicobacter and Microbiota Study Group and Consensus panel, et al. Management of Helicobacter pylori infection-the maastricht V/florence consensus report. Gut. 2017;66(1):6–30.
  • Thung I, Aramin H, Vavinskaya V, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43(4):514–533.
  • Nyssen OP, Bordin D, Tepes B, Hp-EuReg Investigators, et al. European registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40–54.
  • Ford AC, Yuan Y, Forman D, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7(7):Cd005583.
  • Doorakkers E, Lagergren J, Engstrand L, et al. Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies. J Natl Cancer Inst. 2016;108(9):djw132.
  • Doorakkers E, Lagergren J, Engstrand L, et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67(12):2092–2096.
  • Maret-Ouda J, Tao W, Wahlin K, et al. Nordic registry-based cohort studies: possibilities and pitfalls when combining nordic registry data. Scand J Public Health. 2017;45(17_suppl):14–19.
  • Wettermark B, Hammar N, Fored CM, et al. The new swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735.
  • Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. Data resource profile: the danish national prescription registry. Int J Epidemiol. 2017;46(3):798–798.
  • Organization WH. WHO collaborating Centre for drug statistics methodology: ATC classification index with DDDs and guidelines for ATC classification and DDD assignment. Oslo, Norway: Norwegian Institute of Public Health; 2006.
  • Kildemoes HW, Sørensen HT, Hallas J. The danish national prescription registry. Scand J Public Health. 2011;39(7 Suppl):38–41.
  • Sund R. Quality of the finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505–515.
  • Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the swedish national inpatient register. BMC Public Health. 2011;11(1):450.
  • Bakken IJ, Ariansen AMS, Knudsen GP, et al. The norwegian patient registry and the norwegian registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49–55.
  • Rögnvaldsson S, Long TE, Thorsteinsdottir S, et al. Validity of chronic disease diagnoses in icelandic healthcare registries. Scand J Public Health. 2021;:140349482110599. 14034948211059974.
  • Schmidt M, Schmidt SA, Sandegaard JL, et al. The danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
  • Barlow L, Westergren K, Holmberg L, et al. The completeness of the swedish cancer register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33.
  • Sigurdardottir LG, Jonasson JG, Stefansdottir S, et al. Data quality at the icelandic cancer registry: comparability, validity, timeliness and completeness. Acta Oncol. 2012;51(7):880–889.
  • Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231.
  • Pukkala E, Engholm G, Højsgaard Schmidt LK, et al. Nordic cancer registries - an overview of their procedures and data comparability. Acta Oncol. 2018;57(4):440–455.
  • Laugesen K, Ludvigsson JF, Schmidt M, et al. Nordic health Registry-Based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533–554.
  • Sun Y, Zhang J. Helicobacter pylori recrudescence and its influencing factors. J Cell Mol Med. 2019;23(12):7919–7925.
  • Current european concepts in the management of Helicobacter pylori infection. The maastricht consensus report. European Helicobacter Pylori Study Group. Gut. 1997;41(1):8–13.
  • Kosunen TU, Aromaa A, Knekt P, et al. Helicobacter antibodies in 1973 and 1994 in the adult population of vammala, Finland. Epidemiol Infect. 1997;119(1):29–34.
  • Armitage JN, van der Meulen JH, Royal College of Surgeons Co-morbidity Consensus Group Identifying co-morbidity in surgical patients using administrative data with the royal college of surgeons charlson score. Br J Surg. 2010;97(5):772–781.
  • Doorakkers E, Lagergren J, Gajulapuri VK, et al. Helicobacter pylori eradication in the swedish population. Scand J Gastroenterol. 2017;52(6-7):678–685.